RxDoctor Payments Data

Julia Jones, MD

Neurology · Houston, TXNPI 1225024854

Payments from drug & device makers

$45,833in general payments, 2019–2025

Across 959 payments — averaging $47.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$31K
  • AbbVie$2K
  • Novartis$2K
  • Sanofi$2K
  • Pfizer$1K
  • Biogen$1K
  • plus $7K from 53 others

What the payments were for

  • Speaking & faculty fees$26,74958%
  • Travel & lodging$2,1125%
  • Food & beverage$16,87237%
  • Education$1000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)92$30,724
AbbVie(2 entities)145$2,090
Novartis119$1,772
Sanofi44$1,618
Pfizer95$1,388
Biogen51$1,002
Lilly USA, LLC54$904
Lundbeck LLC32$686
EMD Serono, Inc.28$570
Supernus Pharmaceuticals, Inc.39$531
Sunovion Pharmaceuticals Inc.23$434
Teva Pharmaceuticals USA, Inc.20$370
Argenx US, Inc.10$301
Acorda Therapeutics, Inc13$299
Assertio Therapeutics, Inc.25$295
CSL Behring12$272
Arbor Pharmaceuticals, Inc.15$261
Biohaven Pharmaceutical Holding Company Ltd.23$186
Amneal Pharmaceuticals LLC15$186
Biohaven Pharmaceuticals, Inc.18$156
Takeda Pharmaceuticals U.S.A., Inc.6$146
Upsher-smith Laboratories LLC7$128
Neurelis, Inc.1$96
E.r. Squibb & Sons, L.L.C.5$92
Genentech USA, Inc.5$86
Scilex Pharmaceuticals Inc.4$79
TG Therapeutics, Inc.3$78
Axsome Therapeutics, Inc.3$73
Almatica Pharma LLC5$73
Merz North America, Inc.4$69
UCB, Inc.3$62
Stimwave Technologies Incorporated1$60
GE HealthCare3$55
AstraZeneca2$53
Collegium Pharmaceutical, Inc.2$44
Grifols USA, LLC3$44
Neurocrine Biosciences, Inc.3$42
Bristol Myers Squibb2$41
Hospira, Inc.2$38
Impel Pharmaceuticals LLC2$35
Currax Pharmaceuticals LLC2$34
Springworks Therapeutics, Inc.1$27
Tonix Medicines, Inc.1$26
Harmony Biosciences LLC1$26
Amylyx Pharmaceuticals, Inc.1$26
Bioxcel Therapeutics, Inc.1$25
SK Life Science, Inc.1$23
Tanabe Pharma America, Inc.1$23
Medtronic1$22
Averitas Pharma Inc.1$21
Mylan Specialty L.p.1$20
Genentech, Inc.1$18
Merck1$17
GRT US Holding, Inc.1$17
Adamas Pharmaceuticals, Inc.1$17
Avanir Pharmaceuticals, Inc.1$14
Catalyst Pharmaceuticals, Inc.1$14
Impel Pharmaceuticals Inc.1$13
Promius Pharma LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,833 in reported general payments places this provider in the 80th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$228,639
Medicare patients
563
Services billed
15,319

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4626$468,924
CopaxoneGlatiramer Acetate28$188,109
Aimovig AutoinjectorErenumab-Aooe135$104,616
Nurtec OdtRimegepant Sulfate39$55,581
Emgality PenGalcanezumab-Gnlm62$47,980
Teriflunomide18$41,200
Emgality SyringeGalcanezumab-Gnlm17$21,914
Sumatriptan Succinate187$19,466
UbrelvyUbrogepant16$18,936
QuliptaAtogepant17$18,184
Ajovy AutoinjectorFremanezumab-Vfrm15$14,960
Oxtellar XrOxcarbazepine13$13,946
Gabapentin454$7,984
Zolmitriptan OdtZolmitriptan15$7,157
RizatriptanRizatriptan Benzoate196$3,733

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$44$468,92426 claims
Teva Pharmaceuticals USA, Inc.Copaxone$370$188,10928 claims
PfizerNurtec Odt$1,388$55,58139 claims
AbbVieUbrelvy, Qulipta$2,090$37,12033 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$531$13,94613 claims
Upsher-smith Laboratories LLCTopiramate$128$88664 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,246 neurology providers in Texas.

Other neurology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →